- Home
- DRUG vs CGC Comparison
DRUG vs CGC Comparison
Compare DRUG & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- CGC
- Stock Information
- Founded
- DRUG 2019
- CGC N/A
- Country
- DRUG United States
- CGC Canada
- Employees
- DRUG N/A
- CGC N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- CGC Pharmaceuticals and Biotechnology
- Sector
- DRUG Health Care
- CGC Health Care
- Exchange
- DRUG Nasdaq
- CGC Nasdaq
- Market Cap
- DRUG 199.7M
- CGC 239.2M
- IPO Year
- DRUG N/A
- CGC N/A
- Fundamental
- Price
- DRUG $25.41
- CGC $1.13
- Analyst Decision
- DRUG Strong Buy
- CGC Sell
- Analyst Count
- DRUG 7
- CGC 2
- Target Price
- DRUG $83.25
- CGC $2.00
- AVG Volume (30 Days)
- DRUG 60.0K
- CGC 9.2M
- Earning Date
- DRUG 08-13-2025
- CGC 08-08-2025
- Dividend Yield
- DRUG N/A
- CGC N/A
- EPS Growth
- DRUG N/A
- CGC N/A
- EPS
- DRUG N/A
- CGC N/A
- Revenue
- DRUG N/A
- CGC $187,146,485.00
- Revenue This Year
- DRUG N/A
- CGC $11.99
- Revenue Next Year
- DRUG N/A
- CGC $6.84
- P/E Ratio
- DRUG N/A
- CGC N/A
- Revenue Growth
- DRUG N/A
- CGC N/A
- 52 Week Low
- DRUG $0.93
- CGC $0.77
- 52 Week High
- DRUG $79.02
- CGC $8.65
- Technical
- Relative Strength Index (RSI)
- DRUG 43.34
- CGC 40.27
- Support Level
- DRUG $26.09
- CGC $1.18
- Resistance Level
- DRUG $27.50
- CGC $1.33
- Average True Range (ATR)
- DRUG 1.95
- CGC 0.08
- MACD
- DRUG 0.12
- CGC -0.00
- Stochastic Oscillator
- DRUG 44.62
- CGC 4.55
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.